DESTIN — The managing partners of EC Medical Diagnostics say they've made no secret that $70 "rapid" tests conducted on AJ's Seafood & Oyster Bar property were to detect antibodies and not the ...

The EC’s approval is based on the Phase III HD21 trial outcomes, which showed that the Adcetris-based regimen, referred to as BrECADD, met its co-primary efficacy and safety endpoints.